Answers are grounded in this paper and cite their sources.
INTRODUCTION: Polycythaemia vera (PV) is characterised by chronic inflammation and immune dysregulation, but circulating dendritic cell (DC) subsets have not been well characterised. We evaluated circulating DC subsets and inflammatory cytokines in PV and explored their associations with clinical features. METHODS: This cross-sectional case-control study included 112 patients with PV and 30 community based controls frequency matched by age group and sex. Plasmacytoid DCs, conventional DC1 (cDC1), and conventional DC2 (cDC2) were quantified by flow cytometry, and serum IL-6, IL-8, and IL-10 levels were measured by ELISA. Associations with risk category, age, prior thrombosis, splenomegaly, treatment status, and symptom burden were examined. RESULTS: Patients with PV had lower total DC counts and percentages than controls (0.020 vs 0.034 ×10⁹/L and 0.26% vs 0.50%; both p<0.001), primarily reflecting lower cDC1 counts and percentages (0.015 vs 0.028 ×10⁹/L and 0.19% vs 0.42%; both p<0.001). Serum IL-6, IL-8, and IL-10 levels were higher in PV (all p<0.001). Lower cDC2 counts in high risk patients may reflect age, a component of PV risk classification. The association between older age and lower cDC2 counts was no longer statistically significant after adjustment for cytoreductive treatment. Splenomegaly was associated with lower total DC and cDC1 counts. cDC1 percentages remained lower in untreated patients than in controls. DC measures were not associated with prior thrombosis or MPN-10 symptom burden, and cytokine levels did not correlate with absolute DC subset counts. CONCLUSION: PV is associated with reduced circulating DCs, particularly cDC1, alongside increased inflammatory cytokines. Untreated patients had lower cDC1 percentages, but their absolute cDC1 counts were not significantly different from those of controls. A contribution of cytoreductive treatment to the lower absolute cDC1 counts in the overall PV cohort cannot be excluded. Longitudinal studies with disease comparator groups are required to determine its specificity and clinical relevance.
No takes yet. Share an insight, caveat, or question.
Şişman et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: